Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that EGFR activating variants status confers therapeutic sensitivity to Dacomitinib in patients with Non-Small Cell Lung Cancer.

The Republic of Ireland's Health Service Executive (HSE) has approved dacomitinib for reimbursement as a monotherapy treatment option for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.

This statement is based on a regulatory approval from the Health Service Executive:

Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations

Citation

Dacomitinib Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6894/565_V3_Dacomitinib.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2019-11-01	Health Service Executive	Indication approved for reimbursement.